Sunshine Biopharma Inc. (NASDAQ: SBFM) announced the completion of a public offering that raised approximately $6 million in gross proceeds before fees and expenses.

The pharmaceutical company sold 12 million units at $0.50 each, with each unit containing one share of common stock or one pre-funded warrant, plus two Series C warrants. The Series C warrants allow holders to purchase additional shares at $0.50 per share and expire five years from issuance.

If all Series C warrants are exercised, the company could receive up to approximately $12 million in additional proceeds, bringing total potential gross proceeds to $18 million. The company stated no assurance exists that warrant holders will exercise their rights.

Sunshine Biopharma plans to use net proceeds for general corporate purposes and working capital. Aegis Capital Corp. served as the exclusive placement agent for the offering.

The company operates in oncology, antivirals and other therapeutic areas. It currently markets 60 generic prescription drugs in Canada and plans 12 additional launches in 2026. The company is developing K1.1 mRNA, a therapeutic candidate targeting liver cancer, and a PLpro protease inhibitor for coronavirus infections.

The Securities and Exchange Commission declared effective a registration statement filed for the offering on May 18, 2026.